228 related articles for article (PubMed ID: 11468419)
21. Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.
Haraguchi S; Ho SK; Morrow M; Goodenow MM; Sleasman JW
J Leukoc Biol; 2011 Oct; 90(4):653-60. PubMed ID: 21504949
[TBL] [Abstract][Full Text] [Related]
22. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.
Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J
Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744
[TBL] [Abstract][Full Text] [Related]
23. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
[TBL] [Abstract][Full Text] [Related]
24. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
Kim JY; Park YJ; Lee BM; Yoon S
Anticancer Res; 2019 Jul; 39(7):3757-3765. PubMed ID: 31262902
[TBL] [Abstract][Full Text] [Related]
25. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
26. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.
Atzori C; Angeli E; Mainini A; Agostoni F; Micheli V; Cargnel A
J Infect Dis; 2000 May; 181(5):1629-34. PubMed ID: 10823762
[TBL] [Abstract][Full Text] [Related]
28. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Lucia MB; Anu R; Handley M; Gillet JP; Wu CP; De Donatis GM; Cauda R; Gottesman MM
Br J Cancer; 2011 Aug; 105(4):513-22. PubMed ID: 21829205
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Lai S; Lai H; Celentano DD; Vlahov D; Ren S; Margolick J; Lima JA; Bartlett JG
AIDS Patient Care STDS; 2003 May; 17(5):211-9. PubMed ID: 12816615
[TBL] [Abstract][Full Text] [Related]
30. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
31. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233
[TBL] [Abstract][Full Text] [Related]
32. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.
Savarino A; Lucia MB; Rastrelli E; Rutella S; Golotta C; Morra E; Tamburrini E; Perno CF; Boelaert JR; Sperber K; Cauda R
J Acquir Immune Defic Syndr; 2004 Mar; 35(3):223-32. PubMed ID: 15076236
[TBL] [Abstract][Full Text] [Related]
33. The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients.
Adams GB; Pym AS; Poznansky MC; McClure MO; Weber JN
AIDS Res Hum Retroviruses; 1999 Apr; 15(6):551-9. PubMed ID: 10221532
[TBL] [Abstract][Full Text] [Related]
34. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.
Haas DW; Wu H; Li H; Bosch RJ; Lederman MM; Kuritzkes D; Landay A; Connick E; Benson C; Wilkinson GR; Kessler H; Kim RB
J Acquir Immune Defic Syndr; 2003 Nov; 34(3):295-8. PubMed ID: 14600574
[TBL] [Abstract][Full Text] [Related]
35. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Lenhard JM; Furfine ES; Jain RG; Ittoop O; Orband-Miller LA; Blanchard SG; Paulik MA; Weiel JE
Antiviral Res; 2000 Aug; 47(2):121-9. PubMed ID: 10996400
[TBL] [Abstract][Full Text] [Related]
36. Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.
Chinn LW; Gow JM; Tse MM; Becker SL; Kroetz DL
J Antimicrob Chemother; 2007 Jul; 60(1):61-7. PubMed ID: 17510066
[TBL] [Abstract][Full Text] [Related]
37. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Perloff MD; von Moltke LL; Fahey JM; Daily JP; Greenblatt DJ
AIDS; 2000 Jun; 14(9):1287-9. PubMed ID: 10894301
[No Abstract] [Full Text] [Related]
38. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
[TBL] [Abstract][Full Text] [Related]
40. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
